Replacement of Uridine with N1-Methylpseudouridine has been utilized in the COVID-19 mRNA vaccines developed by both Pfizer-BioNTech and Moderna. Research shows that incorporation of N1-Methylpseudouridine increases mRNA vaccine effectiveness through enhanced protein expression combined with low immunogenicity. Read more…



Jenabioscience Logo



N1-Methylpseudouridine: Increase mRNA vaccine effectiveness


Replacement of Uridine with N1-Methylpseudouridine has been utilized in the COVID-19 mRNA vaccines developed by both Pfizer-BioNTech and Moderna.

Research suggests that incorporation of N1-Methylpseudouridine increases mRNA vaccine effectiveness through enhanced protein expression combined with low immunogenicity. Read more…
Read more...


Responsible for content / Imprint:
Jena Bioscience GmbH
Loebstedter Str. 71 | 07749 Jena | Germany
Phone: +49 – 3641 – 6285 000 | Fax: +49 – 3641 – 6285 100 | E-Mail: info@jenabioscience.com
Register Court: Amtsgericht Jena, HRB 207171 | VAT No.: DE 195825742
Managing Directors: Thomas Billert | Dr. Mathias Grün


DIN EN ISO 9001 and DIN EN ISO 14001



Jena Bioscience Facebook Jena Bioscience Twitter Jena Bioscience Youtube Jena Bioscience LinkedIn

visit our website